The FDA has required a REMS for extended-release and long-acting (ER/LA) opioid analgesics.
Misuse and abuse of opioids has grown to be a serious public health concern about addiction, overdose, and death. REMS-compliant training is a critical component of the ER/LA Opioid Analgesics REMS program.
On July 9, 2012, the FDA approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications. The REMS introduces new safety measures to reduce risks and improve safe use of ER/LA opioids while continuing to provide access to these medications for patients in pain.
You can access free online REMS-compliant CME activities on ER and LA opioids CME activities by getting the QuantiaMD mobile app for your smartphone or mobile tablet.
Post a Comment